Pre-Made Timigutuzumab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
TrasGEX (timigutuzumab) is another antibody that has been glyco-optimized to enhance antibody-dependent cell-mediated cytotoxicity. … HuA21 is a chimeric antibody targeted to subdomain I of the ErbB2 extracellular domain and it has been shown to markedly suppress the growth of trastuzumab-resistant cells.